Aurantii Fructus extract alleviates DSS-induced colitis in mice via regulating NF-κB and Nrf2/HO-1 signaling pathways and modulating intestinal microbiota
Open Access
- 16 October 2025
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Nutrition
- Vol. 12, 1661040
Abstract
Background: Ulcerative colitis (UC) is a chronic inflammatory bowel disease characterized by progressive loss of intestinal function, highlighting an urgent need for effective therapeutics. This study aimed to investigate the protective effects of Aurantii Fructus extract (AFE) on dextran sulfate sodium (DSS)-induced UC in mice and its impact on the gut microbiota.Methods: The chemical components of AFE were identified using high-performance liquid chromatography (HPLC). A murine model of DSS-induced colitis was established, and the therapeutic efficacy of AFE was assessed through the disease activity index (DAI), colon length measurement, and histopathological examination. Inflammatory status and oxidative stress markers were evaluated by enzyme-linked immunosorbent assay (ELISA) and western blotting, while the expression of tight junction proteins was analyzed via immunohistochemistry. Additionally, cecal contents were subjected to 16S rRNA gene sequencing to analyze changes in the intestinal microbiota.Results: AFE treatment significantly alleviated the severity of colitis, as evidenced by reduced DAI scores, attenuated colon shortening, and improved histopathological damage. It restored the expression of the tight junction protein ZO-1 in the colon. AFE also markedly reduced the levels of pro-inflammatory cytokines (TNF-α, IL-6, and IL-1β) and suppressed the activation of the NF-κB pathway. Concurrently, AFE enhanced antioxidant capacity by increasing glutathione (GSH) levels, decreasing malondialdehyde (MDA), and activating the Nrf2/HO-1 signaling pathway. Furthermore, AFE treatment inhibited the proliferation of pathogenic bacteria and restored the homeostasis of the gut microbiota.Conclusion: The findings demonstrate that AFE confers a protective effect against DSS-induced UC. The underlying mechanism is associated with the inhibition of the NF-κB pathway, activation of the Nrf2/HO-1 antioxidant pathway, enhancement of the intestinal barrier, and restoration of gut microbiota homeostasis.Keywords
This publication has 54 references indexed in Scilit:
- Analysis of quality evaluation and optimal harvest period of Aurantii Fructus from different sources using UHPLC‐Q‐TOF‐MS/MSPhytochemical Analysis, 2024
- Safflower polysaccharide ameliorates acute ulcerative colitis by regulating STAT3/NF-κB signaling pathways and repairing intestinal barrier functionBiomedicine & Pharmacotherapy, 2024
- Potential effects of fructus aurantii ethanol extracts against colitis-associated carcinogenesis through coordination of Notch/NF-κB/IL-1 signaling pathwaysBiomedicine & Pharmacotherapy, 2022
- Astragalus polysaccharide prevents ferroptosis in a murine model of experimental colitis and human Caco-2 cells via inhibiting NRF2/HO-1 pathwayEuropean Journal of Pharmacology, 2021
- Rapid antidepressant‐like effect of Fructus Aurantii depends on cAMP‐response element binding protein/Brain‐derived neurotrophic facto by mediating synaptic transmissionPhytotherapy Research, 2020
- Hesperetin ameliorates DSS-induced colitis by maintaining the epithelial barrier via blocking RIPK3/MLKL necroptosis signalingEuropean Journal of Pharmacology, 2020
- Therapeutic effect of n-butanol fraction of Huang-lian-Jie-du Decoction on ulcerative colitis and its regulation on intestinal flora in colitis miceBiomedicine & Pharmacotherapy, 2020
- Pharmacokinetic study of precisely representative antidepressant, prokinetic, anti-inflammatory and anti-oxidative compounds from Fructus aurantii and Magnolia BarkChemico-Biological Interactions, 2020
- Mucispirillum schaedleri Antagonizes Salmonella Virulence to Protect Mice against ColitisCell Host & Microbe, 2019
- Effect of Fecal Microbiota Transplantation on 8-Week Remission in Patients With Ulcerative ColitisJAMA, 2019